Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

ABSTRACT:

Background

Interindividual pharmacokinetic variability may influence the clinical benefit or toxicity of cabozantinib in metastatic renal cell carcinoma (mRCC). We aimed to investigate the exposure-toxicity and exposure-response relationship of cabozantinib in unselected mRCC patients treated in routine care.

Methods

This ambispective multicenter study enrolled consecutive patients receiving cabozantinib in monotherapy. Steady-state trough concentration (Cmin,ss) within the first 3 months after treatment initiation was used for the PK/PD analysis with dose-limiting toxicity (DLT) and survival outcomes. Logistic regression and Cox proportional-hazards models were used to identify the risk factors of DLT and inefficacy in patients, respectively.

Results

Seventy-eight mR

SUBMITTER: Blanchet B 

PROVIDER: S-EPMC10950854 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature